Chemed (CHE) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CHE shares.
View CHE analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month target prices for Chemed's stock. Their CHE share price forecasts range from $576.00 to $610.00. On average, they expect the company's share price to reach $593.00 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts price targets for CHE or view top-rated stocks among Wall Street analysts.

Chemed's stock was trading at $510.43 at the beginning of 2023. Since then, CHE stock has increased by 0.7% and is now trading at $513.8950.
View the best growth stocks for 2023 here.

Chemed saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 511,700 shares, a decline of 21.0% from the August 15th total of 648,000 shares. Based on an average daily volume of 71,900 shares, the days-to-cover ratio is currently 7.1 days. Currently, 3.5% of the shares of the stock are sold short.
View Chemed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our CHE earnings forecast.

Chemed Co. (NYSE:CHE) announced its earnings results on Wednesday, July, 26th. The company reported $4.71 earnings per share for the quarter, missing the consensus estimate of $5.09 by $0.38. The firm earned $553.80 million during the quarter, compared to analyst estimates of $562.54 million. Chemed had a trailing twelve-month return on equity of 34.65% and a net margin of 10.36%. The business's revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business earned $4.84 EPS.

Chemed announced a quarterly dividend on Friday, August 4th. Investors of record on Monday, August 14th will be given a dividend of $0.40 per share on Tuesday, September 5th. This represents a $1.60 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Friday, August 11th. This is an increase from the stock's previous quarterly dividend of $0.38.
Read our dividend analysis for CHE.

ETFs with the largest weight of Chemed (NYSE:CHE) stock in their portfolio include VictoryShares THB Mid Cap ESG ETF (MDCP), Formidable Fortress ETF (KONG), First Trust Dorsey Wright Momentum & Low Volatility ETF (DVOL), Opus Small Cap Value Plus ETF (OSCV), Inspire Faithward Mid Cap Momentum ETF (GLRY), Natixis Vaughan Nelson Select ETF (VNSE), FIS Biblically Responsible Risk Managed ETF (PRAY) and Dividend Performers ETF (IPDP).

Chemed (NYSE:CHE) pays an annual dividend of $1.60 per share and currently has a dividend yield of 0.31%. The company has been increasing its dividend for 15 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 10.67%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHE will have a dividend payout ratio of 7.17% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CHE.

Chemed issued an update on its FY 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $19.90-$20.10 for the period, compared to the consensus estimate of $20.92. The company issued revenue guidance of -.

1 employees have rated Chemed Chief Executive Officer Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among the company's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.39%), William Blair Investment Management LLC (3.72%), Kayne Anderson Rudnick Investment Management LLC (3.43%), Durable Capital Partners LP (3.03%), State Street Corp (2.94%) and Impax Asset Management Group plc (1.98%). Insiders that own company stock include David Patrick Williams, Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee and Thomas P Rice.
View institutional ownership trends.

Shares of CHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $513.90.

Chemed (NYSE:CHE) has a market capitalization of $7.75 billion and generates $2.19 billion in revenue each year. The company earns $249.62 million in net income (profit) each year or $15.00 on an earnings per share basis.

The company employs 14,167 workers across the globe.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The official website for the company is www.chemed.com. The company can be reached via phone at (513) 762-6690 or via fax at 513-762-6590.